Skip to content

Clinical trials

Completed Phase 2 Acquired Immunodeficiency Syndrome trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Acquired Immunodeficiency Syndrome Phase: Phase 2 Status: Completed Clear all

241 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20013
20027
20034
20043
200513
20069
200710
20089
200916
20109
20116
20124
20135
201411
20152
20162
20178
20183
20194
20205
20213
20221
20231
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed241

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)60
ViiV Healthcare12
Gilead Sciences7
GlaxoSmithKline6
National Center for Complementary and Integrative Health (NCCIH)6
Tibotec Pharmaceuticals, Ireland6
Hoffmann-La Roche5
Johns Hopkins University4
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.4
Boston Medical Center3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Acquired Immunodeficiency Syndrome241
HIV Infections158
AIDS-Related Complex38
Sarcoma, Kaposi16
Infections13
AIDS-Related Opportunistic Infections11
Cytomegalovirus Retinitis9
Cytomegalovirus Infections6
Anemia5
Multiple Acyl Coenzyme A Dehydrogenase Deficiency5

Trials

Showing 1 to 25 of 241. Each trial links to its page on Pharma Observatory.

141 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.